Goldman Sachs has cut its price target for Bristol-Myers Squibb from $63 to $61.

Oct 30, 2026, 11:18 AM ETOpinionRead the original at marketscreener.com

Bad for BMY

Goldman lowered its target for Bristol-Myers Squibb from $63 to $61, showing a less positive view. The report gives no new company results to confirm or counter that view.

BMY · Bristol-Myers Squibb

AI read · Bad for BMY

The AI's read

That is a warning about one analyst's view of BMY shares, not a report of weaker sales or drug results. The supplied data show BMY shares rose about 2% that day, but that move does not change the analyst's lower estimate.

Get alerts for BMY

Follow Bristol-Myers Squibb (BMY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BMY

Free on the App Store and Google Play, or on the web.